Tech Company Financing Transactions
HDAX Therapeutics Funding Round
On 9/5/2024, HDAX Therapeutics raised $3.2 million in Seed funding from FACIT, Seedfolio and Toronto Innovation Acceleration Partners.
Transaction Overview
Company Name
Announced On
9/5/2024
Transaction Type
Venture Equity
Amount
$3,200,000
Round
Seed
Investors
FACIT (Lead Investor)
Seedfolio (Lead Investor)
Toronto Innovation Acceleration Partners (Lead Investor)
Proceeds Purpose
The company intends to use the funds to support its progress towards preclinical development candidate nomination and further advancement of its pipeline programs.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
333 Bay Street 2400
Toronto, Ontario, M5H 2T6
CA
Toronto, Ontario, M5H 2T6
CA
Phone
Undisclosed
Website
Email Address
Overview
We are dedicated to bringing transformative therapies to patients -- empowering them to embrace life to its fullest. Born out of the lab of Professor Patrick Gunning at the University of Toronto, a serial entrepreneur with a successful track record, HDAX Therapeutics was created with a foundation in translational science and a mission to advance revolutionary treatments.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Nabanita Nawar
Chief Operating Officer
Pimyupa Manaswiyoungkul
Browse more venture capital transactions:
Prev: 9/5/2024: Daisy venture capital transaction
Next: 9/5/2024: E-PAL venture capital transaction
Share this article
About Our VC Transactions Data
We report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs